SWX:ROPPharmaceuticals
Roche Holding (SWX:ROP) Valuation Check As Key Immunology And Neurology Milestones Draw Attention
Roche Holding (SWX:ROP) is back in focus after regulators accepted a key filing for Gazyva in systemic lupus erythematosus, along with new Phase III data for fenebrutinib and Enspryng in multiple sclerosis and MOGAD.
See our latest analysis for Roche Holding.
Despite a series of positive trial readouts and the FDA accepting the Gazyva filing, Roche Holding’s CHF313.1 share price has a 30 day share price return of 3.03%, a 90 day share price return of 10%, and a 1 year total shareholder return...